CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Immunotherapy in glioblastoma treatment: Current state and future prospects.
Immunotherapy in glioblastoma treatment: Current state and future prospects.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
胶质母细胞瘤仍然是最常见和最具侵袭性的恶性脑肿瘤,预后和治疗前景不佳。尽管采用了积极的标准治疗,如手术切除和放化疗,中位生存率仍然很低。在这方面,考虑到其最近的进展和方法,免疫治疗策略对胶质母细胞瘤变得更具吸引力。在这篇综述中,我们概述了胶质母细胞瘤免疫治疗的现状和进展,涵盖了免疫靶向的基础知识到有前景的策略,如CAR-T 细胞疗法、免疫检查点抑制剂、基于细胞因子的治疗、溶瘤病毒和基于疫苗的技术。最后,讨论了克服各种挑战的创新方法以及该领域的未来前景。
Glioblastoma remains as the most common and aggressive malignant brain tumor, standing with a poor prognosis and treatment prospective. Despite the aggressive standard care, such as surgical resection and chemoradiation, median survival rates are low. In this regard, immunotherapeutic strategies aim to become more attractive for glioblastoma, considering its recent advances and approaches.
In this review, we provide an overview of the current status and progress in immunotherapy for glioblastoma, going through the fundamental knowledge on immune targeting to promising strategies, such as Chimeric antigen receptor T-Cell therapy, immune checkpoint inhibitors, cytokine-based treatment, oncolytic virus and vaccine-based techniques. At last, it is discussed innovative methods to overcome diverse challenges, and future perspectives in this area.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。